Navigation Links
Symic Bio to Present at Upcoming Conferences
Date:2/6/2017

SAN FRANCISCO, Feb. 6, 2017 /PRNewswire/ -- Symic Bio, a clinical-stage biotech company that is developing a new category of therapeutics focused on matrix biology, today announced that Ken Horne, Chief Executive Officer, will present at the following upcoming events:

BIO CEO & Investor Conference

Date: Monday, Feb. 13, 2017

Time: 9:30 a.m. EST

Location: Waldorf Astoria, New York

Cowen and Company Health Care Conference

Date: Monday, March 6, 2017

Time: 3:30 p.m. EST

Location: Boston Marriott Copley Place

About Symic Bio

Symic Bio is a clinical-stage biotech company that is developing a new category of therapeutics that are matrix regulators. Matrix regulators target the non-cellular component of tissue and enable new ways to affect disease and healing processes. Matrix regulators have potential applications in a wide variety of indications. Symic Bio currently has two clinical candidates, SB-030 for the treatment of critical limb ischemia and SB-061 directed at disease modification in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.

For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

Investor Contacts

Gitanjali Jain Ogawa
The Trout Group
(646) 378-2949
gogawa@troutgroup.com

Media Contacts

David Schull or Rich Allan
Russo Partners, LLC
(212) 845-4271
(646) 942-5588
david.schull@russopartnersllc.com
rich.allan@russopartnersllc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-upcoming-conferences-300402276.html


'/>"/>
SOURCE Symic Bio
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Symic Biomedical Announces Appointment of Barbara Yanni and Bill Newell as Independent Directors to its Board
2. Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD
3. Symic Biomedical Advances First Product Candidate, SB-030, into Clinical Development with Treatment of First Patient in SHIELD Trial
4. Symic Biomedical Appoints Kamal Egodage, Ph.D., MBA, VP of Development & Manufacturing and Grace Wong-Sarad, VP and Controller
5. Symic Secures $25 Million in Series A-2 Financing to Advance Clinical-Stage Biotherapeutics Platform
6. Symic Appoints Seema Kantak, Ph.D., Chief Scientific Officer
7. Symic Appoints Rinko Ghosh President and Chief Business Officer
8. Symic to Present at the 18th Annual BIO CEO & Investor Conference
9. Symic to Present at the 23rd Annual BioCentury Future Leaders in the Biotech Industry Conference
10. Symic Bio to Present at the 28th Annual Piper Jaffray Healthcare Conference
11. Symic Bio to Participate in the 2017 East/West CEO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/11/2019)... (PRWEB) , ... June 10, 2019 , ... ... of its distribution network with the appointment of Biofeedback Tech Ltd ... monitoring systems are an essential part of many therapeutic treatments and clinical assessment ...
(Date:6/11/2019)... , ... June 11, 2019 , ... ... derived from human mesenchymal stem cells (MSC-EV) are able to incorporate into human ... In a test on mice, MSC-EVs also increased the cells’ ability to lodge ...
(Date:5/31/2019)... , ... May 30, 2019 , ... ... is pleased to announce the strategic acquisition of Metabiologics, Inc., a globally recognized ... provides Object exclusive ownership and commercialization rights to a full spectrum of botulinum ...
(Date:5/15/2019)... (PRWEB) , ... May 16, 2019 , ... ... water mixtures. As a result, food and beverage products rely on these ingredients ... demand more natural sounding label declarations. This paradigm shift triggers food formulators to ...
Breaking Biology Technology:
(Date:6/25/2019)... ... June 25, 2019 , ... ActX has ... data, easily available from 23andMe, customers can get access to professionally reviewed genetic ... for both 23andMe Ancestry and Health + Ancestry customers., With the ActX + ...
(Date:6/16/2019)... (PRWEB) , ... June 14, 2019 , ... ... Americans invited to lecture at the fifth annual Neodent World Congress. Attended by ... the innovative progress and latest advancements in the world of dentistry. The three-day ...
(Date:6/11/2019)... AUCKLAND, New Zealand (PRWEB) , ... June 12, ... ... a wide range of antibody discovery services, Abveris plans to leverage the Geneious ... , Dr. Colby Souders, Chief Technology Officer at Abveris, says: “The Geneious ...
Breaking Biology News(10 mins):